Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 54 results for fragility

  1. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  29 July 2026

  2. Rheumatoid arthritis: fracture risk assessment (IND109)

    This indicator covers the percentage of patients aged 50 to 90 years with rheumatoid arthritis who have had an assessment of fracture risk using a risk assessment tool adjusted for RA in the preceding 27 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM57

  3. FRAX and QFracture in adults living in residential care:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults living in residential care?

    care:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults living in residential care? Any...

  4. FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of osteoporosis?

    osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of...

  5. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  6. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

  7. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

  8. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  9. Forward view - our priority topics

    Our forward view highlights the areas we will prioritise in the coming year.

  10. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST22)

    Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

  11. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  12. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Number TA161 Date...

  13. Using GP practice lists to identify people at high risk:- What is the clinical and cost effectiveness of using GP practice lists to identify people at high risk of fracture, leading to formal risk assessment and possible treatment?

    details Comes from guidance Osteoporosis: assessing the risk of fragility fracture Number CG146 Date issued August 2012

  14. FRAX and QFracture in adults receiving bone protective therapy:- What is the utility of FRAX and QFracture in adults receiving bone protective therapy?

    details Comes from guidance Osteoporosis: assessing the risk of fragility fracture Number CG146 Date issued August 2012